ALGN · XBRL financial data

Align Technology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ALGN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	960	957*	997	1,028	978	995*	979	1,012	996	1,048*	1,040	1,056
Cost of revenue	297	287*	300	306	296	298*	299	304	356	364*	304	299
Gross profit	663	670*	698	723	682	697*	680	708	639	684*	737	757
Research and development	89	82*	92	92	85	95*	97	96	93	83*	99	102
Selling, general and administrative	408	403*	452	452	434	425*	448	449	418	442*	465	463
Total operating expenses	497	498*	544	576	519	553*	549	545	543	528*	595	603
Operating income (loss)	166	172*	154	147	162	144*	131	163	96	155*	142	154
Income tax expense (benefit)	41	49*	53	47	50	37*	47	49	38	41*	36	40
Net income (loss)	121	124*	105	97	116	104*	93	125	57	136*	113	108
Earnings per share, basic USD per share	1.59	1.64*	1.40	1.28	1.55	1.39*	1.27	1.72	0.78	1.89*	1.58	1.51
Earnings per share, diluted USD per share	1.58	1.64*	1.39	1.28	1.55	1.39*	1.27	1.72	0.78	1.89*	1.57	1.51
Weighted average shares, basic millions of shares	77	76*	75	75	75	74*	74	73	72	72*	71	71
Weighted average shares, diluted millions of shares	77	76*	75	75	75	75*	74	73	72	72*	72	72

Balance sheet

CSV

Fiscal quarters (ALGN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,239	937	866	761	1,042	1,044	873	901	1,005	1,095	1,060	1,103
Marketable securities	45	35	33	21	0	0	—	—	—	—	—	—
Marketable securities, non-current	18	8	4	0	0	0	—	—	—	—	—	—
Accounts receivable	904	903	951	1,020	1,011	996	1,062	1,116	1,099	1,102	1,125	1,148
Inventory	296	297	280	259	254	254	247	244	228	226	215	212
Prepaid and other current assets	218	274	350	351	291	199	220	187	174	166	216	200
Total current assets	2,702	2,447	2,479	2,412	2,597	2,492	2,402	2,448	2,534	2,617	2,655	2,663
Property and equipment, net	1,268	1,291	1,282	1,278	1,290	1,271	1,265	1,261	1,185	1,131	1,108	1,114
Right-of-use asset	119	118	119	122	121	113	113	117	115	108	110	115
Goodwill	404	420	458	454	472	443	458	491	492	492	503	497
Total assets	6,319	6,084	6,156	6,158	6,366	6,215	6,103	6,219	6,234	6,234	6,314	6,418
Accounts payable	100	113	117	106	109	109	125	114	126	121	124	110
Accrued liabilities	614	526	497	555	575	598	546	563	546	537	547	612
Total current liabilities	2,123	2,067	2,023	2,040	2,064	2,038	1,991	1,995	1,966	1,920	1,906	1,909
Lease liability, non-current	99	97	95	98	96	88	86	90	87	83	83	87
Total liabilities	2,517	2,453	2,396	2,400	2,422	2,363	2,309	2,306	2,276	2,185	2,165	2,185
Retained earnings	2,607	2,447	2,503	2,457	2,573	2,484	2,389	2,425	2,417	2,464	2,548	2,596
Total stockholders' equity	3,802	3,630	3,760	3,758	3,944	3,852	3,794	3,913	3,957	4,049	4,149	4,232
Total liabilities and equity	6,319	6,084	6,156	6,158	6,366	6,215	6,103	6,219	6,234	6,234	6,314	6,418
Common shares outstanding (cover page) millions of shares	77	75	75	75	75	74	72	72	72	71	72	71

Cash flows

CSV

Fiscal quarters (ALGN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	121	124*	105	97	116	104*	93	125	57	136*	113	108
Stock-based compensation	40	39*	39	47	49	39*	45	48	48	44*	41	46
Depreciation and amortization	37	34*	33	36	38	38*	39	41	56	102*	57	40
Net cash from operating activities	287*	47*	29	160*	264*	286*	53	129*	189*	223*	151	193*
Purchases of property and equipment	22*	33*	9	53*	30*	23*	25	21*	20*	36*	31	36*
Net cash from investing activities	(4)*	(13)*	(80)	(112)*	(9)*	(54)*	(25)	(31)*	(20)*	(36)*	(132)	(82)*
Proceeds from issuing common stock	12*	0*	14	0*	11*	0*	14	0*	8*	0*	12	0*
Share repurchases	0*	300*	0	150*	0*	203*	201	96*	72*	97*	31	67*
Net cash from financing activities	12*	(350)*	(12)	(152)*	11*	(203)*	(207)	(96)*	(64)*	(97)*	(48)	(67)*
Net change in cash	287*	(301)*	(72)	(104)*	281*	2*	(171)	28*	103*	90*	(35)	43*

Compare with peers

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Align Technology	1,103	1,056	193*	71.0M	—	Q2 FY26 10-QJun 30, 2026
Penumbra	254	410	42*	39.4M	—	Q3 FY26 10-QSep 30, 2026
Medline	2,327	7,685	715*	not reported	—	Q2 FY26 10-QJun 27, 2026
Solventum	403	2,209	227*	170.2M	—	Q2 FY26 10-QJun 30, 2026
Hologic	2,168	1,048	230	223.2M	—	Q1 FY26 10-QDec 27, 2025
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
West Pharmaceutical Services	464	875	190*	69.7M	—	Q3 FY26 10-QSep 30, 2026
Baxter International	1,975	2,976	558*	517.3M	—	Q3 FY26 10-QSep 30, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.